{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:41:19Z","timestamp":1794321679018,"version":"4.9.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.psyneuen.2025.107415","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:37:30Z","timestamp":1742492250000},"page":"107415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review"],"prefix":"10.1016","volume":"176","author":[{"given":"Sigrid","family":"Breit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hubl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2025.107415_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.769309","article-title":"Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta-analysis","volume":"12","author":"Afzal","year":"2021","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"10","key":"10.1016\/j.psyneuen.2025.107415_bib2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamapsychiatry.2024.2412","article-title":"Semaglutide in psychiatry-opportunities and challenges","volume":"81","author":"Agarwal","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.psyneuen.2025.107415_bib3","article-title":"Prevalence and outcomes of depression after bariatric surgery: a systematic review and meta-analysis","volume":"14","author":"Alyahya","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.psyneuen.2025.107415_bib4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.psyneuen.2018.03.005","article-title":"Depression and peripheral inflammatory profile of patients with obesity","volume":"91","author":"Ambr\u00f3sio","year":"2018","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"10.1016\/j.psyneuen.2025.107415_bib5","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/oby.23752","article-title":"Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis","volume":"31","author":"Azuri","year":"2023","journal-title":"Obes. (Silver Spring)"},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib6","first-page":"120","article-title":"The association between diabetes mellitus and depression","volume":"9","author":"B\u0103descu","year":"2016","journal-title":"J. Med Life"},{"issue":"10","key":"10.1016\/j.psyneuen.2025.107415_bib7","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1016\/j.biopsych.2024.02.477","article-title":"242. Adjunctive treatment with semaglutide for cognitive dysfunction in major depressive disorder: reduction in depression scores associated with increased HbA1c function and glucose levels","volume":"95","author":"Badulescu","year":"2024","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.psyneuen.2025.107415_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00406-019-01043-8","article-title":"Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the metabolism in psychiatry (MiP) Study","volume":"270","author":"Barton","year":"2020","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s11695-022-05896-2","article-title":"The association between bariatric surgery and psychiatric disorders: a national cohort study","volume":"32","author":"Becerra","year":"2022","journal-title":"Obes. Surg."},{"key":"10.1016\/j.psyneuen.2025.107415_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharm. Res"},{"issue":"5","key":"10.1016\/j.psyneuen.2025.107415_bib11","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s12325-021-01689-8","article-title":"Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies","volume":"38","author":"Bernardo","year":"2021","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2337\/dc10-1119","article-title":"Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment","volume":"34","author":"Best","year":"2011","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"10.1016\/j.psyneuen.2025.107415_bib14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1463-1326.2010.01196.x","article-title":"LEAD-3 Study Group. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes","volume":"12","author":"Bode","year":"2010","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.psyneuen.2025.107415_bib15","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1111\/dom.15145","article-title":"The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): final patient-reported outcomes at 24 months","volume":"25","author":"Boye","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib16","article-title":"Liraglutide for psychiatric disorders: clinical evidence and challenges","volume":"36","author":"Camkurt","year":"2018","journal-title":"Horm. Mol. Biol. Clin. Invest."},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11695-018-3493-4","article-title":"Risk of suicide and self-harm is increased after bariatric surgery-a systematic review and meta-analysis","volume":"29","author":"Castaneda","year":"2019","journal-title":"Obes. Surg."},{"issue":"17","key":"10.1016\/j.psyneuen.2025.107415_bib18","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","article-title":"Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics","volume":"80","author":"Cernea","year":"2020","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.psyneuen.2025.107415_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib20","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2023.2474","article-title":"Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis","volume":"66","author":"Chen","year":"2023","journal-title":"Eur. Psychiatry"},{"issue":"27","key":"10.1016\/j.psyneuen.2025.107415_bib21","article-title":"Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: a network meta-analysis","volume":"102","author":"Chen","year":"2023","journal-title":"Med. (Baltim. )"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of glp-1 receptor agonists: a systematic review and meta-analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psyneuen.2025.107415_bib24","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fpsyt.2018.00784","article-title":"Feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity","volume":"9","author":"Cuomo","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.psyneuen.2025.107415_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221108064","article-title":"Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review","volume":"13","author":"Deng","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib26","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s43440-021-00274-8","article-title":"Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression","volume":"73","author":"Detka","year":"2021","journal-title":"Pharm. Rep."},{"issue":"17","key":"10.1016\/j.psyneuen.2025.107415_bib27","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-Inflammatory Effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.psyneuen.2025.107415_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/JCP.0000000000001409","article-title":"Effect of exenatide use on cognitive and affective functioning in obese patients with type 2 diabetes mellitus: exenatide use mediates depressive scores through increased perceived stress levels","volume":"41","author":"Eren-Yazicioglu","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.psyneuen.2025.107415_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.psyneuen.2025.107415_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.peptides.2017.11.017","article-title":"GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes","volume":"100","author":"Gault","year":"2018","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/dc23-2459","article-title":"Differential effects of type 2 diabetes treatment regimens on diabetes distress and depressive symptoms in the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)","volume":"47","author":"Gonzalez","year":"2024","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jdiacomp.2011.03.002","article-title":"Psychological and quality of life changes in patients using GLP-1 analogues","volume":"25","author":"Grant","year":"2011","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.psyneuen.2025.107415_bib34","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fnins.2019.01112","article-title":"Glucagon-like peptide-1: a focus on neurodegenerative Diseases","volume":"13","author":"Grieco","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.psyneuen.2025.107415_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109720","article-title":"Association between diabetes and mood disorders and the potential use of anti-hyperglycemic agents as antidepressants","volume":"95","author":"Grigolon","year":"2019","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2025.107415_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","article-title":"Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis","volume":"82","author":"Guirguis","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.psyneuen.2025.107415_bib37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/a-1844-1176","article-title":"The Antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis","volume":"54","author":"Guo","year":"2022","journal-title":"Horm. Metab. Res"},{"key":"10.1016\/j.psyneuen.2025.107415_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2019.01.016","article-title":"Brain insulin resistance: a treatment target for cognitive impairment and anhedonia in depression","volume":"315","author":"Hamer","year":"2019","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3810\/pgm.2012.07.2577","article-title":"Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians","volume":"124","author":"Hasnain","year":"2012","journal-title":"Post. Med"},{"issue":"9","key":"10.1016\/j.psyneuen.2025.107415_bib40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tem.2022.06.005","article-title":"GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?","volume":"33","author":"Horska","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.psyneuen.2025.107415_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.psyneuen.2025.107415_bib42","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-024-06243-z","article-title":"Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study","author":"Hurtado","year":"2024","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2869.2012.01030.x","article-title":"Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea","volume":"22","author":"Idris","year":"2013","journal-title":"J. Sleep. Res"},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s13300-020-00985-w","article-title":"Effect of orally administered semaglutide versus dulaglutide on diabetes-related quality of life in japanese patients with type 2 diabetes: the PIONEER 10 randomized, active-controlled trial","volume":"12","author":"Ishii","year":"2021","journal-title":"Diabetes Ther."},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/09513590.2018.1505848","article-title":"The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls","volume":"35","author":"Kahal","year":"2019","journal-title":"Gynecol. Endocrinol."},{"issue":"5","key":"10.1016\/j.psyneuen.2025.107415_bib47","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.soard.2019.01.008","article-title":"Mental disorders and weight change in a prospective study of bariatric surgery patients: 7 years of follow-up","volume":"15","author":"Kalarchian","year":"2019","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7570\/jomes20010","article-title":"Current long-term pharmacotherapies for the management of obesity","volume":"29","author":"Kim","year":"2020","journal-title":"J. Obes. Metab. Syndr."},{"issue":"11","key":"10.1016\/j.psyneuen.2025.107415_bib49","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1111\/dom.15864","article-title":"Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: a comprehensive analysis of the global pharmacovigilance database","volume":"26","author":"Kim","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.psyneuen.2025.107415_bib50","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3389\/fphar.2020.01270","article-title":"Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function","volume":"11","author":"Kim","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.psyneuen.2025.107415_bib51","series-title":"What Is Best for Weigh Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue","author":"Klair","year":"2023"},{"issue":"19","key":"10.1016\/j.psyneuen.2025.107415_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/cob.12146","article-title":"Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management","volume":"6","author":"Kolotkin","year":"2016","journal-title":"Clin. Obes."},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cob.12226","article-title":"Improvements in health-related quality of life over 3\u2009years with liraglutide 3.0\u2009mg compared with placebo in participants with overweight or obesity","volume":"8","author":"Kolotkin","year":"2018","journal-title":"Clin. Obes."},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12589","article-title":"Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial","volume":"13","author":"Kolotkin","year":"2023","journal-title":"Clin. Obes."},{"key":"10.1016\/j.psyneuen.2025.107415_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2337\/db14-0668","article-title":"GLP-1 and exendin-4 transiently enhance GABAA receptor-mediated synaptic and tonic currents in rat hippocampal CA3 pyramidal neurons","volume":"64","author":"Korol","year":"2015","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib58","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/dom.15426","article-title":"Treatment effect of semaglutide 2.4\u2009mg on health-related quality of life from STEP 1 SF-6D derived from SF-36 with Australian weights","volume":"26","author":"Kral","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/oby.23946","article-title":"Efficacy and safety of semaglutide 2.4\u2009mg according to antidepressant use at baseline: a post hoc subgroup analysis","volume":"32","author":"Kushner","year":"2024","journal-title":"Obes. (Silver Spring)"},{"issue":"7","key":"10.1016\/j.psyneuen.2025.107415_bib60","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psyneuen.2025.107415_bib61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.genhosppsych.2022.07.006","article-title":"A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis","volume":"78","author":"Lee","year":"2022","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.psyneuen.2025.107415_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113830","article-title":"Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients","volume":"299","author":"Lee","year":"2021","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib63","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/acps.13509","article-title":"Degree of exposure to psychotropic medications and mortality in people with bipolar disorder","volume":"147","author":"Lin","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.psyneuen.2025.107415_bib64","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/07853890.2018.1511917","article-title":"Increased risk for major depressive disorder in severely obese patients after bariatric surgery - a 12-year nationwide cohort study","volume":"50","author":"Lu","year":"2018","journal-title":"Ann. Med"},{"issue":"3","key":"10.1016\/j.psyneuen.2025.107415_bib65","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2010.2","article-title":"Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies","volume":"67","author":"Luppino","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.psyneuen.2025.107415_bib66","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1007\/s11695-023-06595-2","article-title":"Impact of preoperative psychiatric profile in bariatric surgery on long-term weight outcome","volume":"33","author":"L\u00fcscher","year":"2023","journal-title":"Obes. Surg."},{"key":"10.1016\/j.psyneuen.2025.107415_bib67","article-title":"Suicidal thoughts and self-injurious behavior associated with glucagon-like peptide-1 receptor agonists - a review","author":"Maideen","year":"2024","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.psyneuen.2025.107415_bib68","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J. Affect Disord."},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JCP.0000000000001803","article-title":"Liraglutide in obese or overweight individuals with stable bipolar disorder","volume":"44","author":"McElroy","year":"2024","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2025.107415_bib70","first-page":"31","article-title":"Potential roles of glucagon-like peptide-1 and its analogues in dementia targeting impaired insulin secretion and neurodegeneration","volume":"12","author":"Mehan","year":"2022","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.psyneuen.2025.107415_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115709","article-title":"Temporal associations of BMI and glucose parameters with depressive symptoms among US adults","volume":"332","author":"Meshkat","year":"2024","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib72","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pcd.2015.06.003","article-title":"Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study","volume":"10","author":"Moulton","year":"2016","journal-title":"Prim. Care Diabetes"},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib73","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s11605-018-3903-x","article-title":"Mental illness has a negative impact on weight loss in bariatric patients: a 4-year follow-up","volume":"23","author":"M\u00fcller","year":"2019","journal-title":"J. Gastrointest. Surg."},{"issue":"3","key":"10.1016\/j.psyneuen.2025.107415_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13547","article-title":"Impact of treatment with GLP-1RAs on suicide attempts in adults persons with type 2 diabetes: a retrospective comparative effectiveness study based on a global TriNetX health research database","volume":"16","author":"Nassar","year":"2024","journal-title":"J. Diabetes"},{"issue":"10","key":"10.1016\/j.psyneuen.2025.107415_bib75","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/phar.1639","article-title":"Liraglutide: a new option for the treatment of obesity","volume":"35","author":"Nuffer","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.psyneuen.2025.107415_bib76","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/dom.12963","article-title":"Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials","volume":"19","author":"O\u2019Neil","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.psyneuen.2025.107415_bib77","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.psyneuen.2025.107415_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1394506","article-title":"Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice","volume":"15","author":"Pantanetti","year":"2024","journal-title":"Front Endocrinol."},{"issue":"9","key":"10.1016\/j.psyneuen.2025.107415_bib79","article-title":"A double-blind placebo-controlled study of exenatide for the treatment of weight gain associated with olanzapine in overweight or obese adults with bipolar disorder, major depressive disorder, schizophrenia or schizoaffective disorder","volume":"77","author":"Patino","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000506404","article-title":"AMTCO Group. Impact of depression on weight variation after bariatric surgery: a three-year observational study","volume":"13","author":"Pedro","year":"2020","journal-title":"Obes. Facts"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib81","article-title":"Glucagon-like peptide analogs are superior for diabetes and weight control in patients on antipsychotic medications: a retrospective cohort study","volume":"22","author":"Perlis","year":"2020","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psyneuen.2025.107415_bib83","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231165169","article-title":"SM. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series","volume":"13","author":"Prasad","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2025.107415_bib84","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jad.2020.01.154","article-title":"Obesity increases the risk of depression in children and adolescents: results from a systematic review and meta-analysis","volume":"267","author":"Rao","year":"2020","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.psyneuen.2025.107415_bib85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1477-7525-11-217","article-title":"Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study","volume":"11","author":"Reaney","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib86","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series","volume":"85","author":"Richards","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib87","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-021-01000-1","article-title":"Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects","volume":"41","author":"Rognoni","year":"2021","journal-title":"Clin. Drug Invest."},{"issue":"6","key":"10.1016\/j.psyneuen.2025.107415_bib88","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.psyneuen.2025.107415_bib89","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"STEP 8 investigators. effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 Randomized Clinical Trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.psyneuen.2025.107415_bib90","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23335","article-title":"GLP-1 Receptor agonists and suicidality-caution is needed","volume":"7","author":"Salvo","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.psyneuen.2025.107415_bib91","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/oby.23563","article-title":"Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis","volume":"30","author":"Sarma","year":"2022","journal-title":"Obes. (Silver Spring)"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/acps.13690","article-title":"Liraglutide 3.0\u2009mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: a 26-week open-label feasibility study","volume":"150","author":"Sass","year":"2024","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.psyneuen.2025.107415_bib93","first-page":"233","article-title":"Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes","volume":"57","author":"Savchenko","year":"2019","journal-title":"Rom. J. Intern Med"},{"issue":"3","key":"10.1016\/j.psyneuen.2025.107415_bib94","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ando.2023.03.006","article-title":"Metabolic disorders induced by psychotropic drugs","volume":"84","author":"Scheen","year":"2023","journal-title":"Ann. Endocrinol. (Paris)"},{"issue":"8","key":"10.1016\/j.psyneuen.2025.107415_bib95","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"10","key":"10.1016\/j.psyneuen.2025.107415_bib96","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"71","author":"Serretti","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2025.107415_bib97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2020.02.015","article-title":"Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)","volume":"124","author":"Siskind","year":"2020","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.psyneuen.2025.107415_bib98","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euroneuro.2024.07.001","article-title":"GLP-1 agonists and risk of suicidal thoughts and behaviours: Confound by indication once again? a narrative review","volume":"87","author":"Strumila","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib99","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.psyneuen.2025.107415_bib100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jdi.12906","article-title":"Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes:a randomized controlled trial","volume":"10","author":"Takase","year":"2019","journal-title":"J. Diabetes Invest."},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.orcp.2020.11.002","article-title":"The use of anti-obesity medications in people with mental illness as an adjunct to lifestyle interventions - Effectiveness, tolerability and impact on eating behaviours: a 52-week observational study","volume":"15","author":"Tham","year":"2021","journal-title":"Obes. Res Clin. Pr."},{"issue":"1415","key":"10.1016\/j.psyneuen.2025.107415_bib102","first-page":"76","article-title":"Pterli R. Bariatrische Chirurgie-ein Auslaufmodell?","volume":"104","author":"Timper","year":"2023","journal-title":"Schweiz \u00c4rzteztg"},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib103","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-8587(19)30405-X","article-title":"Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression","volume":"8","author":"Van Sloten","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib104","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3892\/etm.2023.12054","article-title":"Therapeutic management of atypical antipsychotic-related metabolic dysfunctions using GLP-1 receptor agonists: a systematic review","volume":"26","author":"Vasiliu","year":"2023","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.psyneuen.2025.107415_bib105","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib106","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1467-789X.2012.01031.x","article-title":"Obesity and addiction: neurobiological overlaps","volume":"14","author":"Volkow","year":"2013","journal-title":"Obes. Rev."},{"key":"10.1016\/j.psyneuen.2025.107415_bib107","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/DDDT.S10180","article-title":"Liraglutide in the management of type 2 diabetes","volume":"4","author":"Wajcberg","year":"2010","journal-title":"Drug Des. Devel Ther."},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib108","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib109","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/dc12-0702","article-title":"Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"36","author":"Wang","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.psyneuen.2025.107415_bib110","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.psyneuen.2025.107415_bib111","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s00125-014-3302-0","article-title":"Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)","volume":"57","author":"de Wit","year":"2014","journal-title":"Diabetologia"},{"issue":"18","key":"10.1016\/j.psyneuen.2025.107415_bib112","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3390\/ijms21186969","article-title":"Clinical evidence of antidepressant effects of insulin and anti-hyperglycemic agents and implications for the pathophysiology of depression-a literature review","volume":"21","author":"Woo","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.psyneuen.2025.107415_bib113","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrad077","article-title":"Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials","volume":"7","author":"Wu","year":"2023","journal-title":"BJS Open"},{"key":"10.1016\/j.psyneuen.2025.107415_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1244432","article-title":"Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review","volume":"14","author":"Xie","year":"2023","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.psyneuen.2025.107415_bib115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jpsychores.2018.05.008","article-title":"\"Interleukin, tumor necrosis factor-alpha and C-reactive protein profiles in melancholic and non-melancholic depression: a systematic review","volume":"111","author":"Yang","year":"2018","journal-title":"J. Psychosom. Res"},{"key":"10.1016\/j.psyneuen.2025.107415_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.psyneuen.2025.107415_bib117","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/1753-0407.12198","article-title":"Weight loss effect of glucagon-like peptide-1 mimetics on obese\/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2015","journal-title":"J. Diabetes"},{"issue":"1","key":"10.1016\/j.psyneuen.2025.107415_bib118","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453025001386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453025001386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:48:51Z","timestamp":1770410931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453025001386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":118,"alternative-id":["S0306453025001386"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2025.107415","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2025.107415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107415"}}